#United States #Colorado Springs #Neurocrine #Tardive Dyskinesia #NEI Fall Congress

Neurocrine Biosciences to Present at the 2026 NEI Fall Congress

Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading biopharmaceutical company, is set to participate in the 2026 Neuroscience Education Institute (NEI) Fall Congress happening from November 5 to 8 in Colorado Springs, Colorado. This year, the company will be highlighting its journey through the neuropsychiatry field and its expanding pipeline during a dedicated session titled "Inspired by Patients, Driven by Science: The Neurocrine Story."

In this session, attendees will have the opportunity to dive deep into the science and developments that have defined Neurocrine’s more than 30 years of experience in the pharmaceutical industry.

Dimitri E. Grigoriadis, Ph.D., a notable figure at Neurocrine, stated, "We are excited to share our scientific journey with the neuroscience community, discussing both the hurdles and lessons learned that have shaped our methodology. Our efforts are rooted in a patient-focused approach and guided by the evolution of scientific insights."

Focus on Neuropsychiatry

Neurocrine is not only sharing its historical perspective but also presenting new research findings regarding major psychiatric disorders. These include major depressive disorder (MDD) and schizophrenia—two conditions that collectively impact millions globally. The company will also address tardive dyskinesia (TD), a movement disorder often linked to prolonged use of certain psychiatric medications.

During the NEI, Neurocrine will feature multiple poster presentations detailing their advancements and findings. Here’s what attendees can expect:

• - Major Depressive Disorder Research: Neurocrine will present several studies focused on the glutamatergic dysfunction in MDD, emphasizing the importance of understanding patient experiences with cognitive impairment amid treatment protocols.

- Poster Titles:
- Beyond Monoamines: The Role of Glutamatergic Signaling in Major Depressive Disorder
- Cognitive Impairment in Major Depressive Disorder: A Patient-Identified Priority
- MDD Treatment Sequences and Continuity

• - Schizophrenia Insights: Presentations will also cover the impact of cardiometabolic comorbidities following the initiation of atypical antipsychotic therapies.

- Poster Title:
- Development of Cardiometabolic Comorbidity in Adults with Schizophrenia

• - Tardive Dyskinesia Findings: TD significantly influences patients' quality of life. Neurocrine will reveal findings from their KINECT-PRO™ study, which evaluates the effects of INGREZZA® (valbenazine), a specific treatment approved for TD.

- Poster Titles:
- Burden of Tardive Dyskinesia on Employment
- Positive Effects of FDA-Approved Treatments

Future Goals

The overarching theme of Neurocrine's participation at NEI will be their commitment to continuing the development of groundbreaking therapies that alleviate serious neuropsychiatric conditions.

With a diverse pipeline that includes treatments for various psychiatric disorders, Neurocrine is focused on innovation and patient care. The insights shared during the Congress highlight the company's dedication to advancing mental health treatments through scientific research and collaboration.

Neurocrine is more than just a pharmaceutical company; it is a leader striving to transform the landscape of neuroscience and mental health. By focusing on patient needs, they aim to address some of the most challenging psychiatric conditions faced by society today.

For those attending the NEI Congress, the insight shared by Neurocrine could prove invaluable, potentially reshaping future approaches to neuropsychiatric treatment strategies. Don't miss the opportunity to learn about their journey, challenges, and triumphs in neuroscience at this year’s NEI Fall Congress.